市場調查報告書
商品編碼
1467654
2024-2032 年血管內動脈瘤修復市場報告(按適應症(腹主動脈瘤、胸主動脈瘤、胸腹主動脈瘤等)、產品、性別、年齡、最終用戶和地區)Endovascular Aneurysm Repair Market Report by Indication (Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, and Others), Product, Gender, Age, End-User, and Region 2024-2032 |
IMARC Group年,全球血管內動脈瘤修復(EVAR)市場規模達30億美元。 。
動脈瘤是指動脈壁因衰弱或變性而增大。它通常與煙草消費和吸煙有關。在患有動脈粥狀硬化、高膽固醇和結締組織疾病等疾病的族群中,動脈瘤的盛行率也較高。血管內動脈瘤修復(EVAR)是指修復這些動脈瘤的微創手術。 EVAR 手術是透過將覆蓋支架(帶有一層織物的金屬網管)插入動脈的薄弱區域來進行的。這為血液流動提供了一條通道,而不會積聚在凸起處,並防止其破裂。如今,市面上有多種用於治療動脈瘤的設備。
EVAR治療比傳統手術相對安全,因為不需要進行手術。因此,該技術可以縮短住院時間並加快康復速度。由於動脈瘤的盛行率以及老年人口的不斷成長,醫療保健提供者擴大採用血管內治療。人們對該手術潛在益處的認知不斷提高,進一步支持了這一點。此外,全球各國政府正在實施多項計劃,以改善成本結構並提高患者對 EVAR 設備和治療程序可用性的認知。為此,醫療機構正在開發 EVAR 設備和技術,以提供更快的恢復和更少的併發症。例如,已經創建了增強的移植技術,可以實現短著陸區的治療並提高對動脈曲率的順應性。這些技術進一步幫助提高了 EVAR 手術的成功率。
The global endovascular aneurysm repair (EVAR) market size reached US$ 3.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.
An aneurysm refers to the enlargement of the arterial wall due to weakness or degeneration. It is generally associated with tobacco consumption and smoking. The prevalence of aneurysms is also higher among people with medical conditions such as atherosclerosis, high cholesterol levels, and connective tissue disorder. Endovascular aneurysm repair (EVAR) refers to a minimally invasive procedure or surgery that is performed to repair these aneurysms. EVAR procedure is performed by inserting a covered stent, a metal mesh tube with a layer of fabric, into the weak area of the artery. This provides a route for the blood to flow without accumulating in the bulge and prevents it from bursting. Nowadays, multiple devices are available in the market that are used to treat aneurysms.
The EVAR treatment is comparatively safer than traditional procedures, as there is no need for performing surgery. As a result, this technique results in short hospital stays and quicker recovery. Due to the prevalence of aneurysms, along with the growing geriatric population, endovascular treatment is increasingly being adopted by healthcare providers. This has further been supported by the rising awareness of the potential benefits of the procedure. Also, governments across the globe are undertaking several programs to improve the cost structure and spread awareness about the availability of EVAR devices and treatment procedures among patients. In line with this, healthcare institutions are developing EVAR devices and technologies that offer faster recovery and fewer complications. For instance, enhanced graft technologies have been created, which allow treatments with short landing zones and improve conformability to the artery curvature. These technologies have further helped in increasing the success rate of EVAR procedures.
IMARC Group provides an analysis of the key trends in each sub-segment of the global endovascular aneurysm repair (EVAR) market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on indication, product, gender, age and end-user.
Abdominal Aortic Aneurysm (AAA)
Thoracic Aortic Aneurysm (TAA)
Thoracoabdominal Aortic Aneurysm (TAAA)
Others
Percutaneous EVAR
Fenestrated EVAR
Aortic Stents and TAA Grafts
Others
Male
Female
Pediatric
Adult
Geriatric
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Asia Pacific
Europe
North America
Middle East and Africa
Latin America
The report has also analyzed the competitive landscape of the market with some of the key players being Medtronic plc, Cook Group Incorporated, W. L. Gore & Associates, Inc., Bolton Medical, Inc., Gamida Cell Ltd., JOTEC GmbH, Getinge AB (Maquet), Shanghai MicroPort Medical (Group) Co., Ltd., Terumo Corporation, Endologix, Inc., Lombard Medical Limited, and Cardinal Health, Inc.